Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population

被引：13
|
作者：
Reichardt, P. [1 ]
Hartmann, J. T. [2 ]
Hall, K. Sundby [3 ]
Eriksson, M. [4 ]
Schuette, J. [5 ]
Ramadori, G. [6 ]
Hohenberger, P. [7 ]
Duyster, J. [8 ]
Leinonen, M. [9 ]
Joensuu, H. [10 ]
机构：
[1] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
[2] Univ Tubingen, Med Oncol Hematol Immunol Rheumatol & Pulmonol, Med Ctr, Tubingen, Germany
[3] Norwegian Radium Hosp, Oslo Univ Hosp, Oncol, Oslo, Norway
[4] Lund Univ, Skane Univ Hosp, Oncol, Lund, Sweden
[5] Marien Hosp, Oncol Hematol, Dusseldorf, Germany
[6] Univ Gottingen, Gastroenterol Endocrinol, D-37073 Gottingen, Germany
[7] Univ Mannheim, Med Ctr, Surg Oncol Thorac Surg, D-68131 Mannheim, Germany
[8] Tech Univ Munich, Klinikum Rechts Isar, Internal Med 3, D-80290 Munich, Germany
[9] 4Pharma Ltd, Turku, Finland
[10] Univ Helsinki, Cent Hosp, Oncol, Helsinki, Finland
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70130-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
31LBA
引用
收藏
页码：15 / 15
页数：1
相关论文
共 35 条
  • [31] LOGIST - A Local Observational GIST registry: First interim analysis after a mean observation time of 14.3 months. A non-interventional registry to observe patients with gastrointestinal stroma tumours (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77)
    Reichardt, P.
    Stuebs, P.
    Fahlke, J.
    Stoelzel, U.
    Quietzsch, D.
    Pustowka, A.
    Reichardt, A.
    Krajinovic, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S889 - S889
  • [32] LOGIST - A Local Observational GIST registry: Second interim analysis after a mean observation time of 22.3 months - comparison of site organisational impact on diagnosis and treatment - A non-interventional registry to observe patients with gastrointestinal stroma tumours (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77)
    Krajinovic, K.
    Quietzsch, D.
    Stuebs, P.
    Cameron, S.
    Gellert, K.
    Wilhelm, M.
    Killing, B.
    Croner, R.
    Kopp, H-G
    Will, U.
    Wardelmann, E.
    Reichardt, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 153 - 153
  • [33] ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
    Soverini, Simona
    De Santis, Sara
    Monaldi, Cecilia
    Mancini, Manuela
    Giai, Valentina
    Cerrano, Marco
    Capodanno, Isabella
    Bonifacio, Massimiliano
    Abruzzese, Elisabetta
    Iurlo, Alessandra
    Castagnetti, Fausto
    Sancetta, Rosaria
    Levato, Luciano
    Fava, Carmen
    Tiribelli, Mario
    Cavazzini, Francesco
    Miggiano, Maria Cristina
    Bolli, Niccolo
    Tafuri, Agostino
    Lucchesi, Alessandro
    Vallisa, Daniele
    Lunghi, Monia
    Musolino, Caterina
    Bruno, Samantha
    Mosca, Cristina
    Ciriello, Mauro
    Marsili, Giovanni
    Piciocchi, Alfonso
    Fazi, Paola
    Cavo, Michele
    Janssen, Jeroen J. W. M.
    Westerweel, Peter E.
    Pane, Fabrizio
    BLOOD, 2024, 144 : 3158 - 3160
  • [34] Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
    Casali, P. G.
    Le Cesne, A.
    Velasco, A. P.
    Kotasek, D.
    Rutkowski, P.
    Hohenberger, P.
    Fumagalli, E.
    Judson, I. R.
    Italiano, A.
    Gelderblom, H.
    Penel, N.
    Hartmann, J. T.
    Duffaud, F.
    Goldstein, D.
    Martin-Broto, J.
    Gronchi, A.
    Wardelmann, E.
    Marreaud, S.
    Zalcberg, J. R.
    Litiere, S.
    Blay, J-Y
    ANNALS OF ONCOLOGY, 2021, 32 (04) : 533 - 541
  • [35] Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
    Casali, Paolo G.
    Le Cesne, Axel
    Velasco, Andres Poveda
    Kotasek, Dusan
    Rutkowski, Piotr
    Hohenberger, Peter
    Fumagalli, Elena
    Judson, Ian R.
    Italiano, Antoine
    Gelderblom, Hans
    Adenis, Antoine
    Hartmann, Jorg T.
    Duffaud, Florence
    Goldstein, David
    Broto, Javier M.
    Gronchi, Alessandro
    Dei Tos, Angelo P.
    Marreaud, Sandrine
    van der Graaf, Winette T.A.
    Zalcberg, John R.
    Litiere, Saskia
    Blay, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) : 4276 - 4283
1234